Xeris Biopharma Holdings Inc Revenue Growth Rates (XERS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Xeris Biopharma Holdings Inc   (NASDAQ: XERS)
 

XERS's Revenue Growth by Quarter and Year

Xeris Biopharma Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/XERS/growth
https://api.csimarket.com/api/v1/companies/XERS/fundamentals
https://api.csimarket.com/api/v1/companies/XERS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
XERS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 107.23
2nd Quarter June 92.10
1st Quarter March 83.13
FY 282.46

XERSs Annual Revenue
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2025 $ 291.85 millions
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2024 $ 203.07 millions
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2023 $ 163.91 millions
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2022 $ 110.25 millions
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2021 $ 49.59 millions




XERS Revenue third quarter 2026 Y/Y Growth Comment
Xeris Biopharma Holdings Inc reported Revenue rise of 44.16% year on year in the third quarter 2026, to $ 107.23 millions, this is lower than Xeris Biopharma Holdings Inc 's recent average Revenue surge of 5151.14%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 74 other companies have achieved higher Revenue growth. While Xeris Biopharma Holdings Inc ' s Revenue jump of 44.16% ranks overall at the positon no. 778 in the third quarter 2026.


XERS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 44.16 %
2nd Quarter June 28.74 %
1st Quarter March 38.27 %
FY   -

Financial Statements
Xeris Biopharma Holdings Inc 's third quarter 2026 Revenue $ 107.23 millions XERS's Income Statement
Xeris Biopharma Holdings Inc 's third quarter 2025 Revenue $ 74.38 millions Quarterly XERS's Income Statement


XERS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 16.42 %
2nd Quarter June 10.79 %
1st Quarter March -3.12 %
FY (Year on Year)   -


Back to XERS Growth rate Comparisons >> Back to XERS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #75
Healthcare Sector #167
Overall #778

Revenue Y/Y Growth Statistics
High Average Low
104877.78 % 5151.14 % -100 %
(Dec 31 2020)   (Sep 30 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #75
Healthcare Sector #167
Overall #778
Revenue Y/Y Growth Statistics
High Average Low
104877.78 % 5151.14 % -100 %
(Dec 31 2020)   (Sep 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Xeris Biopharma Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
17444.44 % 557.88 % -100 %
(Dec 31 2019)  


XERS's III. Quarter Q/Q Revenue Comment
Xeris Biopharma Holdings Inc achieved in the III. Quarter 2026 below company average Revenue jump of 16.42% quarter on quarter, to $ 107.23 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 3.97% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Xeris Biopharma Holdings Inc 's Revenue growth quarter on quarter, overall rank is 771.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #771
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #771
Revenue Q/Q Growth Statistics
High Average Low
17444.44 % 557.88 % -100 %
(Dec 31 2019)  


XERS's III. Quarter Q/Q Revenue Comment
Xeris Biopharma Holdings Inc achieved in the III. Quarter 2026 below company average Revenue jump of 16.42% quarter on quarter, to $ 107.23 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 3.97% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Xeris Biopharma Holdings Inc 's Revenue growth quarter on quarter, overall rank is 771.


Xeris Biopharma Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 335.41
Y / Y Revenue Growth (TTM) 36.33 %
Year on Year Revenue Growth Overall Ranking # 479
Seqeuential Revenue Change (TTM) 6.53 %
Seq. Revenue Growth (TTM) Overall Ranking # 1442


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Xeris Biopharma Holdings Inc 's cumulative twelve months Revenue were $ 335 millions, company would post below average annual Revenue growth of 6.53% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Xeris Biopharma Holdings Inc 's Revenue growth from the 92.1% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 458 to 479.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 114
Overall # 479

Revenue TTM Y/Y Growth Statistics
High Average Low
15523.16 %
 806.96 %
22.72 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 244
S&P 500 # 1442
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Xeris Biopharma Holdings Inc 's cumulative twelve months Revenue were $ 335 millions, company would post below average annual Revenue growth of 22.72% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Xeris Biopharma Holdings Inc 's Revenue growth from the 92.1% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 458 to 479.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 114
Overall # 479

Revenue TTM Y/Y Growth Statistics
High Average Low
15523.16 %
806.96 %
22.72 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 244
S&P 500 # 1442




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XERS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions


About Xeris Biopharma Holdings Inc Revenue Growth Rates (XERS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.